Nucleic Acid Test (NAT) for Blood Transfusion

March 3, 2026

Why in the News?

The Supreme Court has agreed to examine whether the Nucleic Acid Test (NAT) should be made compulsory in blood banks to ensure safer blood transfusion practices.

What’s in Today’s Article?

NAT (Background, Basics, Constitutional Angle, Cost & Feasibility Concerns, Recent Incidents, Regulatory Framework, etc.)

Background of the Case

The matter came before a Bench of the Chief Justice of India and two other judges after a petition was filed by an NGO seeking mandatory implementation of NAT across blood banks in India.
The petitioner argued that the right to safe blood transfusion forms part of the fundamental right to life under Article 21 of the Constitution.
The plea emphasised that NAT is a safer and more sensitive testing mechanism compared to existing screening methods and is necessary to prevent transfusion-transmitted infections.
The Court has asked the petitioner to submit additional data on cost-effectiveness, State-level implementation, and feasibility before taking a final view.

What is the Nucleic Acid Test (NAT)?

NAT is a highly sensitive molecular diagnostic technique that detects the genetic material (DNA or RNA) of viruses in donated blood.
It is capable of identifying infections such as Human Immunodeficiency Virus (HIV), Hepatitis B, and Hepatitis C.
Unlike traditional serological tests, NAT reduces the “window period”, the time between infection and detectability, thereby enhancing blood safety.
Currently, many blood banks in India primarily use Enzyme-Linked Immunosorbent Assay (ELISA) tests, which are less expensive but comparatively less sensitive during early infection stages.

Constitutional Dimension and Right to Life

The petitioner has argued that access to safe and infection-free blood is an integral component of the right to life under Article 21.
The Supreme Court has previously interpreted Article 21 expansively to include the right to health, medical care, and dignity.
In this context, ensuring safe blood transfusion aligns with the constitutional obligation of the State to protect public health.
The Court’s decision to examine the issue indicates recognition of the broader public health and human rights implications.

Cost and Feasibility Concerns

During the hearing, the Bench raised questions regarding the financial feasibility of making NAT mandatory across all States.
The Court asked whether economically weaker States, already struggling with budgetary constraints, would be able to afford NAT in government blood banks and hospitals.
While the petitioner argued that the costs of NAT are comparatively low, the Court highlighted that additional financial burdens could affect States with limited fiscal capacity.
The Bench has directed the petitioner to file an affidavit detailing:

This indicates that the Court is adopting a data-driven approach before considering mandatory nationwide implementation.

Public Health Context and Recent Incidents

The issue has gained urgency due to reported cases of children contracting HIV allegedly due to contaminated blood transfusions.
The petition referred to cases involving Thalassemia patients, who require frequent blood transfusions and are particularly vulnerable to infected blood.
Thalassemia is an inherited blood disorder in which the body cannot produce adequate haemoglobin. India has a high burden of Thalassemia patients, increasing the demand for safe and regular blood transfusions.
The case assumes greater significance against the backdrop of reported incidents in Madhya Pradesh and Jharkhand, where children were found HIV-positive following allegedly contaminated transfusions.
Such incidents have been described as “preventable tragedies” in the petition.
These events have reignited debate over the adequacy of existing blood screening mechanisms.

Policy and Regulatory Framework

Blood safety in India is regulated under the Drugs and Cosmetics Act, 1940, and supervised by the National Blood Transfusion Council (NBTC) and State Blood Transfusion Councils.
Currently, mandatory screening includes tests for HIV, Hepatitis B, Hepatitis C, malaria, and syphilis using serological methods. NAT is not uniformly mandated across all blood banks.
Introducing compulsory NAT would require:

The decision, therefore, has implications for both health governance and fiscal policy.

See All